Carpal Tunnel Syndrome Tied to Increased Incidence of Heart Failure

FRIDAY, July 14, 2023 (HealthDay News) -- Carpal tunnel syndrome (CTS) is associated with an increased incidence of new-onset heart failure, according to a research letter published online July 12 in JAMA Network Open.
Mark Luedde, M.D., from the University of Kiel in Germany, and colleagues conducted a retrospective cohort study involving adult patients from 1,284 general practices in Germany with an initial diagnosis of CTS to examine the association with heart failure. The cohort included 81,898 patients with CTS, who were propensity score-matched to 81,898 without CTS.
The researchers found that 10 years after the index date, 8.4 and 6.2 percent of patients with and those without CTS, respectively, received a diagnosis of heart failure (incidence, 8.7 versus 6.1 cases per 1,000 patient-years). In a regression analysis, a significant association was seen between CTS and subsequent heart failure diagnosis (hazard ratio, 1.39). The association was comparable for women and men (hazard ratios, 1.40 and 1.38, respectively). CTS was significantly associated with heart failure among patients aged 61 to 70 years and older than 70 years (hazard ratios, 1.48 and 1.48, respectively), but not among those aged 18 to 40, 41 to 50, or 51 to 60 years.
"Our study reveals an association between CTS and heart failure," the authors write. "Thus, we point to a new role for surgeons together with general practitioners in the early detection of important internal diseases, a chance for better treatment, and an improved prognosis of these diseases."
Related Posts
La administración de Biden invertirá 100 millones para aliviar la escasez de trabajadores de la salud
https://consumer.healthday.com/b-10-15-biden-admin... Credit: HealthDay
Bevacizumab, Aflibercept Compared for Neovascular AMD
MONDAY, Dec. 5, 2022 (HealthDay News) -- For patients with neovascular...
Living Review Compares Treatments for Atopic Dermatitis
WEDNESDAY, March 23, 2022 (HealthDay News) -- Abrocitinib, 200 mg daily, and...
Risankizumab Safe, Effective at 52 Weeks for Psoriatic Arthritis
WEDNESDAY, Jan. 11, 2023 (HealthDay News) -- Risankizumab provides long-term...
